Key result
External counterpulsation significantly preserved VEGF-A and VEGFR-2 levels compared to sham in patients with refractory angina, indicating improved angiogenesis.
Why the study?
External counterpulsation is postulated to improve angiogenesis through increased shear stress, but its effects on VEGF-A, VEGFR-2, and flow-sensitive miR-92a had not been evaluated in a sham-controlled manner.
Does external counterpulsation improve angiogenesis biomarkers (VEGF-A, VEGFR-2, miR-92a) in patients with refractory angina?
RCT (n=50)
Triple-blind (patients, outcome assessors, data analysts)
1:1 ratio, computer-based random numbers
No
Does external counterpulsation improve angiogenesis biomarkers (VEGF-A, VEGFR-2, miR-92a) in patients with refractory angina?
Absolute Event Rate: 1% vs -136%
p-value: p=0.026
ECP preserves VEGF-A/VEGFR-2 in refractory angina; supports angiogenesis hypothesis but leaves miR-92a role open for larger trials.
Objective: External counterpulsation (ECP) provides long-term benefits of improved anginal frequency and exercise tolerance in patients with refractory angina (RA). This is postulated as a result of improved angiogenesis and endothelial function through an increase in shear stress. Angiogenesis is mainly represented by vascular endothelial growth factor-A (VEGF-A) and its receptor, vascular endothelial growth factor receptor-2 (VEGFR-2). The microRNA-92a (miR-92a) is a flow-sensitive miRNA that regulates atherosclerosis and angiogenesis in response to shear stress. Thus, ECP beneficial effect might be achieved through interaction between VEGF-A, VEGFR-2, and miR-92a. This study aims to evaluate the ECP effect on VEGF-A, VEGFR-2, and miR-92a in patients with RA in a sham-controlled manner. Methods: This was a randomized sham-controlled trial, enrolling 50 patients with RA who have coronary artery disease (CAD). Participants were randomized (1:1 ratio) to 35 sessions of either ECP (n = 25) or sham (n = 25), each session lasting for 1 h. Plasma levels of VEGF-A and VEGFR-2 were assayed by the ELISA technique. The quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to measure miR-92a circulating levels in plasma. Result: External counterpulsation significantly preserved VEGF-A and VEGFR-2 level compared to sham [ΔVEGF-A: 1 (−139 to 160) vs.−136 (−237 to 67) pg/ml, p = 0.026; ΔVEGFR-2: −171(-844 to +1,166) vs. −517(−1,549 to +1,407) pg/ml, p = 0.021, respectively]. Circulating miR-92a increased significantly in ECP [5.1 (4.2–6.4) to 5.9 (4.8–6.4), p < 0.001] and sham [5.2 (4.1–9.4) to 5.6 (4.8–6.3), p = 0.008] post-intervention. The fold changes tended to be higher in ECP group, although was not statistically different from sham [fold changes ECP = 4.6 (0.3–36.5) vs. sham 2.8 (0–15), p = 0.33)]. Conclusion: External counterpulsation improved angiogenesis by preserving VEGF-A and VEGFR-2 levels. Both ECP and sham increased miR-92a significantly, yet the changes were not different between the two groups. (Study registered on www.clinicaltrials.gov , no: NCT03991871, August 8, 2019, and received a grant from the National Health Research and Development of Ministry of Health of Indonesia, No: HK.02.02/I/27/2020).
No takes yet. Share an insight, caveat, or question.
Ambari et al. (2021) conducted an RCT in Refractory Angina (n=50). External counterpulsation (ECP) vs. Sham procedure (identical frequency, 75 mmHg pressure) was evaluated on Change in VEGF-A level from baseline (pg/ml) (p=0.026). External counterpulsation significantly preserved VEGF-A and VEGFR-2 levels compared to sham in patients with refractory angina, indicating improved angiogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: